Tufts Center for the Study of Drug Development

What Tufts Center for the Study of Drug Development does

Tufts Center for the Study of Drug Development (Tufts CSDD) is an independent, nonprofit academic research center within Tufts University School of Medicine that conducts empirical research on drug development performance, efficiency, and economics. Founded in 1976 by Dr. Louis Lasagna at the University of Rochester and relocated to Tufts in Boston in 1984, the center maintains a 13-person core team (4 faculty, 6-person research team, 3 administrators) supplemented by fellows, consultants, and affiliate faculty. Tufts CSDD conducts 12-15 empirical research studies annually and disseminates findings through 361 peer-reviewed articles, 169 conference presentations, 20 white papers, and its bi-monthly Impact Reports subscription publication; the center is celebrating its 50th anniversary in 2026 with an Impact Interview Series on YouTube.

Tufts CSDD's portfolio spans research services, subscription publications, and professional development. Core research offerings include longitudinal databases and recurring studies, single-sponsor and consortium research (PACT, PALADIN), surveys, and the FDA Quarterly Performance Tracker. The 53-year-running Postgraduate Course in Clinical Pharmacology, Drug Development & Regulation ($2,832 regular rate) and the Leadership for Drug Development Teams course anchor the training portfolio, alongside customized on-site/virtual programs delivered to organizations including Arrakis Therapeutics, Takeda Pharmaceuticals, and Northeastern Bouvé College. Annual roundtables attract 45-75 senior delegates per program and produce published themes. Distribution is direct/field-based for Circle of Supporters enterprise sponsorships and self-serve via online registration for individual Impact Report subscriptions ($675/year individual, $150 single issue) and course enrollments.

Tufts CSDD operates a hybrid revenue model in which approximately 55% of operating expenses are funded by private-sector grants and 45% by public-sector sources. Revenue streams include Circle of Supporters annual memberships (large pharma anchors Eli Lilly, Merck, Sanofi, Pfizer, Roche-Genentech, GSK, Boehringer-Ingelheim), Impact Reports subscriptions, tuition from professional development courses, single-issue publication sales, and government/foundation grants (FDA, U.S. Department of Defense, Bill & Melinda Gates Foundation, PhRMA). The center competes primarily on independent-academic credibility, multi-decade longitudinal datasets, and convening power across pharma, biotech, CROs, regulators, and patient advocacy organizations — and explicitly does not sell products or technology, positioning its intellectual property, publications, education, and consulting services as the basis of value creation.

Name

Tufts Center for the Study of Drug Development

Legal name

Tufts Center for the Study of Drug Development

Website

https://csdd.tufts.edu

Company type

Private

Founded year

1976

Operating status

Operating

Short description

Tufts CSDD is an independent nonprofit academic research center within Tufts University School of Medicine that conducts empirical research on drug development performance, efficiency, and economics for pharmaceutical companies, regulators, foundations, and biotech firms.

Ownership category

akta.pro rank

Product category

Pharmaceutical R&D Research & Education Services

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)

akta.pro secondary industry

Public–Private Partnerships (PPPs) for Global Health (HLAJAOAD)

Keywords

• Drug development research
• Clinical pharmacology education
• Pharmaceutical benchmarking
• Industry consortia facilitation
• Regulatory science insights

Headquarters

HQ city

Medford

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Research Grants and Sponsorship: Primary revenue stream from annual sponsorship through Circle of Supporters program and research grant funding from pharmaceutical companies, biotechnology companies, government agencies (FDA, Department of Defense), foundations (Bill & Melinda Gates Foundation), and trade associations (PhRMA). Organizations provide funding to participate in research priority setting and receive access to findings.
2. Impact Reports Subscriptions: Bi-monthly subscription-based publication presenting original research and data on drug development topics. Individual annual subscription at $675 for 6 issues; corporate multi-user subscriptions available at volume discounts.
3. Professional Development Programs: Tufts CSDD generates revenue from professional development courses including the Postgraduate Course in Clinical Pharmacology, Drug Development & Regulation ($2,832 regular rate; $2,524 for Circle of Supporters), Leadership for Drug Development Teams course, and customized on-site/virtual programs for organizations.
4. Single Issue Publications: Sale of individual Impact Report issues at $150 per single issue. Also single issues of white papers and archived reports available for purchase.

Pricing tiers

Go-to-market motion1 record

Distribution channels6 records

Marketing channels12 records

Core offering

Tufts CSDD is an independent academic research center that conducts empirical research on drug development performance, efficiency, and economics, and translates findings into subscription publications (Impact Reports), professional development courses (Postgraduate Course, Leadership for Drug Development Teams, customized on-site/virtual programs), executive roundtables, white papers, and sponsored research studies for pharmaceutical, biotech, regulatory, and academic audiences.

Product overview

Tufts CSDD is an independent academic research center within Tufts University School of Medicine that offers a portfolio of research services and professional development products. The core offerings include the bi-monthly Tufts CSDD Impact Reports (subscription-based publication), the annual Postgraduate Course in Clinical Pharmacology, Drug Development and Regulation (now in its 53rd year), and the Leadership for Drug Development Teams professional development program. Supporting products include Customized On-Site & Virtual Courses, Roundtables & Forums, and the FDA Quarterly Performance Tracker. Research services encompass Databases & Surveys, Single Sponsors & Working Groups, and Consortia research. Publications include Whitepapers, Peer-Reviewed Articles, and Conference Presentations. The organization conducts 12-15 empirical research studies annually and facilitates industry-wide collaboration through its Circle of Supporters membership program.

Differentiator

Problem solved

Functional benefit

Brands

• PACT: Partnership for Advancing Clinical Trials: A pre-competitive consortium focused on advancing clinical trials through collaborative research and industry partnerships.

Products and services

• Tufts CSDD Impact Reports Bi-monthly subscription-based publication presenting original research, authoritative data, analysis, and insights on essential drug development topics, targeted at pharmaceutical, biotech, and CRO audiences for use in internal presentations and decision support.
• Postgraduate Course in Clinical Pharmacology, Drug Development & Regulation Holistic professional development course providing an overview of the global drug development landscape, with multiple sessions running January-February 2026, attended by physicians, regulators, policy makers, and academic researchers.
• Leadership for Drug Development Teams Highly interactive virtual professional development program highlighting cross-functional leadership, strategic planning, stakeholder alignment, communication, and change management for drug development teams.
• Customized On-Site & Virtual Professional Development Bespoke on-site or virtual training courses covering foundational drug development and regulatory science topics, tailored to specific organizational needs with proposal-based budgeting.
• Roundtables & Forums Invitation-based executive roundtables and forums on strategic drug development topics, typically attracting 45-75 senior-level delegates, with outcomes published in journals and white papers.
• FDA Quarterly Performance Tracker Quarterly subscription-style report tracking FDA performance metrics, industry-agency interactions, meetings, inspections, and regulatory review cycle durations to inform understanding of FDA actions.
• Single-Sponsor, Working Group & Consortium Research Custom research partnerships and working groups conducting empirical studies for individual pharmaceutical, biotechnology, and contract research organizations on specific drug development topics, including facilitated consortia.

Quantifiable outcome

• Phase III protocols average 5.96 million data points but nearly one-third of study procedures do not support primary endpoints
• +6 more outcomes

Named customers11 records

Segments7 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Ten partnerships are on record, tiered core and minor.

• Verana HealthcoreStrategic or Co-development PartnerVerana Health sponsored Tufts CSDD research on the increasing value of real-world data (RWD) and real-world evidence (RWE) in clinical trials. The study, based on interviews with executives from 18 pharmaceutical, biotech, and CRO organizations, found growing adoption of RWD across all phases of drug development with anticipated ROI increases over the next 1-2 years.
• MedablecoreStrategic or Co-development PartnerMedable collaborated with Tufts CSDD to launch the Innovation Evidence Workshop series focused on DCT impact, adoption, and best practices. First workshop held November 19 in Boston with industry leaders from pharma, biotech, CROs, FDA, and academic institutions. Research showed DCT components can reduce enrollment time by 40% and triple enrollment rates.
• Fisher Clinical ServicesminorStrategic or Co-development PartnerFisher Clinical Services funded Tufts CSDD research examining the evolving role of clinical supply chain management in pharmaceutical and biotech companies. Study found 80% of respondents use centralized supply chain structures, 70% rely on manual forecasting, and nearly 60% outsource individual services per trial.
• PACT (Partnership for Advancing Clinical Trials)coreStrategic or Co-development PartnerPre-competitive consortium focused on advancing clinical trials through collaborative research. Tufts CSDD facilitates the consortium producing research on DCTs, patient diversity, and trial efficiency. New DCT analysis released showing decentralized components linked to improved diverse participation.
• PALADIN ConsortiumcoreStrategic or Co-development PartnerConsortium aimed at enhancing efficient patient advocacy-industry collaborations. Tufts CSDD introduced PALADIN and continues to facilitate research and release playbook & resource repository to support collaboration between patient advocacy groups and biopharmaceutical companies.
• TransCelerate BioPharmacoreStrategic or Co-development PartnerCollaborative study with Tufts CSDD analyzing clinical trial data collection practices. Peer-reviewed publication found Phase III protocols average 5.96 million data points with nearly one-third of procedures not supporting primary endpoints. Research offers considerations for modernizing protocol design per ICH E6(R3) guidelines.
• XtalksminorGTM or Marketing PartnerXtalks hosted free webinar featuring Tufts CSDD speakers on AI's role in curating and analyzing real-world data across the pharmaceutical drug development lifecycle. Webinar explored advances in AI expanding access to RWD for study design, patient recruitment, and pharmacovigilance.
• DIA (Drug Information Association)coreStrategic or Co-development PartnerOngoing collaboration including DIA/Tufts CSDD research on AI saving time in drug development, joint publication in Therapeutic Innovation & Regulatory Science, and faculty presentations at DIA Global annual meetings. Partnership includes podcast collaborations and webinar series.
• CISCRP (Center for Information and Study of Clinical Research Participation)minorStrategic or Co-development PartnerKenneth Getz founded CISCRP, a nonprofit dedicated to educating and raising public and patient awareness of the clinical research enterprise. Ongoing affiliation and collaboration between Tufts CSDD and CISCRP on patient engagement and clinical trial literacy initiatives.
• CenterWatchminorStrategic or Co-development PartnerKenneth Getz founded CenterWatch, a leading publisher in the clinical trials industry. One of several businesses he has sold. CenterWatch represents early industry infrastructure development emerging from Tufts CSDD ecosystem.

Scale indicators11 records

Recent moves11 records

Expansion highlights6 records

Broad incumbents

• Pharmaceutical Research and Manufacturers of America (PhRMA): PhRMA is the US pharmaceutical industry trade association that publishes reports on drug development economics and policy. It is a current Tufts CSDD sponsor and overlaps on research themes like development costs and innovation policy, but covers a much broader industry advocacy portfolio.
• Biotechnology Innovation Organization (BIO): BIO is the biotech industry's largest trade association, producing industry benchmark reports on clinical development timelines, regulatory issues, and R&D productivity. It overlaps with Tufts CSDD's research base but operates as a broader industry advocacy and conference organization.
• Parexel International: Parexel is a global CRO that publishes proprietary benchmarks and white papers on clinical trial performance, protocol design, and drug development operations. It overlaps with Tufts CSDD's research themes from a commercial-services perspective rather than as an independent academic center.

Direct peers

• Institute for Clinical and Economic Review (ICER): ICER is an independent, nonprofit research organization that produces data-driven assessments of clinical and economic value in healthcare. It shares Tufts CSDD's positioning as an objective, non-commercial empirical research voice informing drug development and payer decision-making.
• National Pharmaceutical Council (NPC): NPC is a nonprofit health policy research organization that produces empirical research on biopharmaceutical value, real-world evidence, and clinical trial economics. It is directly comparable to Tufts CSDD in operating as an evidence-based research resource serving pharma, regulators, and policymakers.
• IQVIA Institute for Human Data Science: The IQVIA Institute publishes reports on drug development trends, R&D productivity, and clinical trial metrics that closely parallel Tufts CSDD's Impact Reports and longitudinal studies. Both serve pharma R&D leadership with empirical benchmarks on cost, time, and success rates.
• Clinical Trials Transformation Initiative (CTTI): CTTI is a public-private partnership co-founded by FDA and Duke that conducts empirical research and develops recommendations to improve clinical trial quality and efficiency. Tufts CSDD faculty regularly present at CTTI events and the organizations share methodologies, audiences, and sponsors.
• Drug Information Association (DIA): DIA is a global life sciences knowledge-sharing organization that produces peer-reviewed research, hosts conferences, and convenes working groups on drug development and regulatory science, directly overlapping with Tufts CSDD's publications, conferences, and ICH E6 roundtables.

Others

• Association of Clinical Research Organizations (ACRO): ACRO is the CRO industry trade association that conducts research and advocacy on clinical trial operations. It is adjacent to Tufts CSDD because CROs are a key stakeholder in the research base Tufts CSDD studies, though ACRO is an industry advocacy body rather than a research peer.

Emerging players

• FasterCures at the Milken Institute: FasterCures is a center of the Milken Institute focused on accelerating medical research and patient access to therapies. It shares Tufts CSDD's focus on patient engagement, clinical trial efficiency, and cross-stakeholder collaboration in drug development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/TuftsCSDD
• LinkedInlinkedin.com/company/tufts-center-for-the-study-of-drug-development_2

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tufts Center for the Study of Drug Development